FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

The US FDA approved Omisirge, a substantially modified allogeneic cord blood-based cell therapy to quicken the recovery of neutrophils in the body and reduce the risk of infection.